CClinicalTrials.gg
Enrolling by invitationNCT07108244FINDUpdated Jul 6, 2026

Use of [18F]FET PET-MRI to Improve Detection of Pituitary Adenomas in Cushing's Disease

An interventional study of [18F]FET PET-MRI in Cushing Disease, sponsored by University Hospital, Basel, Switzerland. Enrolling by invitation at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-06.

Sponsored by University Hospital, Basel, Switzerland · Not applicable, Interventional, and Diagnostic

Phase
Not applicable
Study type
Interventional
Enrollment
43
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

In ACTH-dependent hypercortisolism it is important to distinguish between Cushing's disease (CD), with ACTH production by a pituitary neuroendocrine tumour (PitNET) and Cushing's syndrome (CS), with ectopic ACTH production. Bilateral inferior petrosal sinus sampling (IPSS) is the gold standard for this distinction, with a diagnostic accuracy of 98%. However, IPSS is an invasive procedure and an indi-rect diagnostic method, rarely providing reliable data on the exact location of the PitNET. This has a major impact on the therapeutic approach, short and long-term remission rates, and other outcomes. Hybrid Positron-emission tomography-Magnetic Resonance Imaging (PET-MRI) using O-(2-[18F]-fluo-roethyl)-L-tyrosine ([18F]FET) is promising in this respect. Recent data published by our research group demonstrate a a sensitivity of 100% a high accuracy in in the precise localization of ACTH-secreting PitNETs. We hypothesize that [18F]FET PET-MRI could become the new non-invasive diagnostic stand-ard, but data regarding a direct comparison between the diagnostic impact of [18F]FET PET-MRI versus IPSS in the differentiation between CD and ectopic CS are lacking. In addition, there are currently no other reliable biomarkers to distinguish the two disorders. The investigators hypothesize that the ACTH-dependent biomarker copeptin could be a valuable addition in this regard. The aim of this prospective diagnostic study is to compare the diagnostic accuracy of [18F]FET-PET-MRI and IPSS in differentiating CD from ectopic CS in patients with ACTH-dependent hypercortisolism.

02

Conditions studied

  • Cushing Disease
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Age ≥18 years
  • Biochemically confirmed ACTH-dependent hypercortisolism, defined as:
  • Non-suppressed ACTH levels plus minimal 2 of the following:
  • Overnight 1mg dexamethasone suppression test > 50 nmol/L
  • Elevated late night salivary cortisol (min. 2/3 measurements)
  • Elevated 24-hours urinary free cortisol (min. 2 measurements)
  • Pituitary microadenoma (\< 10mm) OR negative / inconclusive findings on standard MRI of the pituitary sella-region.
  • Indication for further evaluation with IPSS

Exclusion criteria

Exclusion Criteria:

  • Non-ACTH dependent hypercortisolism
  • Pituitary macroadenoma (≥ 10mm)
  • Suspicion of Pseudo-Cushing's disease (e.g. due to alcohol use disorder, PCO's, obesity, de-pression) according to standard work up / guidelines
  • use of glucocorticosteroids
  • Impaired renal function, defined as eGFR (MDRD) \<30ml/min/1,73 m2. An exception can be made in consultation with the treating physician.
  • Impaired Liver function
  • Pregnancy/breastfeeding. For the latter, temporary discontinuation may be considered.
  • Known allergic reaction to therapeutic radiopharmaceuticals.
04

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
43 participants (estimated)

Study arms

  • Other
    [18F]FET-PET-MRI vs IPSS for diagnosing CD vs ectopic CS in ACTH-dependent cases

    Participants will undergo both \[18F\]FET-PET-MRI and inferior petrosal sinus sampling (IPSS) to evaluate their diagnostic performance in differentiating Cushing's disease from ectopic ACTH secretion. Results of both procedures will be made available to the treating medical team and participants as they become available.

    Diagnostic Test: [18F]FET PET-MRI

Interventions

  • Diagnostic test[18F]FET PET-MRI

    All participants will undergo both \[18F\]fluoroethyltyrosine positron emission tomography-magnetic resonance imaging (\[18F\]FET-PET-MRI) and inferior petrosal sinus sampling (IPSS) as part of the diagnostic work-up for ACTH-dependent hypercortisolism. The purpose is to compare the diagnostic accuracy of these two modalities in distinguishing Cushing's disease from ectopic ACTH secretion. The results from both diagnostic tests will be communicated to the treating medical team and the participant to guide further clinical management.

05

What researchers measure

Primary outcomes

  1. Comparison of the proportion of correct distinctions between CD and ectopic CS in patients with ACTH-dependent hypercortisolism using [18F]FET PET-MRI versus IPSS

    The difference in the proportion of correct distinction between CD and ectopic CS in patients with ACTH-dependent hypercortisolism using \[18F\]FET PET-MRI versus IPSS

    Time frame: Patients will receive standard surgical or radiotherapeutic treatment. The study will collect follow-up data 3-6 months post-treatment without influencing clinical management or requiring study-specific visits.

Secondary outcomes

  1. Copeptin values during IPSS

    Best fit of diagnostic copeptin values for differentiation between CD and ectopic CS with the inferior petrosal sinus sampling (IPSS) after desmopressin injection,

    Time frame: During the IPSS

  2. ACTH values during IPSS

    Best fit of diagnostic ACTH values for differentiation between CD and ectopic CS with the inferior petrosal sinus sampling (IPSS) after desmopressin injection

    Time frame: During the IPSS

  3. Comparison of the diagnostic accuracy between [18F]FET PET-MRI and IPSS for differentiating between CD and ectopic CS in patients with ACTH-dependent hy-percortisolism

    ROC AUC of the \[18F\]FET PET-MRI and IPSS in differentiating CD from ectopic CS Sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of the \[18F\]FET PET-MRI and IPSS for differentiation between CD and ectopic CS

    Time frame: Follow-up data 3-6 months post-treatment

  4. Exact localization of small functional PitNETs in patients with CD using the [18F]FET PET-MRI

    Stated as left, central or right side, assessed by an experienced nuclear medicine physician and neuroradiologist Sensitivity, specificity, PPV and NPV of the \[18F\]FET PET-MRI for the exact localization of small functional PitNETs in patients with CD

    Time frame: perioperative

  5. Exact localization of small functional PitNETs in patients with CD using the inferior petrosal sinus sampling (IPSS)

    Sensitivity, specificity, PPV and NPV of the IPSS for the exact localization of small functional PitNETs in patients with CD

    Time frame: perioperative

  6. Exact localization of small functional PitNETs in patients with CD using the structural MRI

    Sensitivity, specificity, PPV and NPV of the structural MRI for the exact localization of small functional PitNETs in patients with CD

    Time frame: perioperative

06

Study locations

2 sites
  • Erasmus University Medical Centre
    Rotterdam, South Holland 3015, Netherlands
  • University Hospital Basel
    Basel, Canton of Basel-City 4031, Switzerland
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07108244
Lead sponsor
University Hospital, Basel, Switzerland
Collaborators
Erasmus Medical Center
Responsible party
Sponsor
First posted
Aug 6, 2025
Start date
Jun 4, 2026
Primary completion
Jul 30, 2029 (estimated)
Completion
Jul 30, 2029 (estimated)
Last update
Jul 6, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion